-- 週二下午晚些時候，醫療保健類股小幅上漲，紐約證券交易所醫療保健指數小幅走高，道富醫療保健精選行業SPDR ETF (XLV)上漲0.2%。 iShares生物技術ETF (IBB)下跌0.6%。 在產業新聞方面，根據《華爾街日報》週二報道，美國食品藥物管理局(FDA)計劃在今年夏天試點一項利用人工智慧加速新藥臨床試驗的方法，該方法將透過自動化數據收集和提交來實現。該報道引述了對FDA首席人工智慧官傑里米·沃爾什的採訪。 在公司新聞方面，Axogen (AXGN)股價上漲超過6%，此前該公司週二公佈，由於營收大幅增長，第一季調整後每股收益由去年同期的虧損扭虧為盈。 輝瑞（PFE）週二表示，已與三家仿製藥生產商就其治療心肌病變轉甲狀腺素蛋白澱粉樣變性藥物Vyndamax的專利侵權訴訟達成和解協議。這些訴訟已在美國特拉華州地方法院提起。輝瑞股價下跌1.7%。 禮來（LLY）週二宣布，已與Profluent公司達成策略合作，共同開發用於基因藥物的人工智慧設計的重組酶。禮來股價上漲0.6%。 諾華（NVS）週二公佈第一季核心每股收益為1.99美元，低於去年同期的2.28美元。 FactSet調查的分析師先前預期為2.19美元。截至3月31日的第一季淨銷售額為131.1億美元，低於去年同期的132.3億美元。該公司表示，預計2026年核心營業收入將出現個位數百分比的下降。諾華股價上漲0.3%。
Related Articles
Research
Research Alert: Equity Residential Delivers Slight Ffo Beat And Revenue Miss In Q1 2026
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:EQR delivered Q1 2026 FFO of $0.99, beating consensus by $0.02, though rental revenue of $780M slightly missed expectations. The company's blended lease rate of 1.5% remained flat Y/Y, with new lease rates declining 2.8% due to incentives offset by strong renewal rates of 4.7%. We maintain our Hold rating based on operating expense pressure suppressing cash NOI growth in 2026. Management guides for 2026 same-store revenue growth of 1.2%-3.2%, expense growth of 3.0%-4.0%, and cash NOI growth of 0.5%-2.5%, with strength expected in 2H 2026. EQR's coastal market strategy continues demonstrating value, with San Francisco leading at 6.5% revenue growth and New York at 4.6%, while expansion markets like Denver (-5.9%) and Atlanta (-2.0%) face new supply pressure. EQR has premium coastal markets where limited new supply enables pricing power, though higher operating costs remain a risk. The development pipeline totals $863M for 1,824 units when complete. Planned property acquisitions are $165M in 2026.
$EQR
Asia
Rua Bioscience Notes 'Significant Contraction' in Australian Medical Cannabis Prescribing Volumes Amid Regulatory Review
Rua Bioscience (NZE:RUA) said the Australian market has experienced "significant contraction" in medical cannabis prescribing volumes amid a Therapeutic Goods Administration review of the safety of unapproved products, according to a Wednesday filing with the New Zealand bourse.However, medicinal cannabis is showing "strong signs of maturity and growth" in international markets, especially in Europe, in the face of recent international developments and discourse of a global economic slowdown, Rua added.The company recently established RUA genetics in Canada, the second-largest cannabis market in the world after the US, adding to its presence in Germany, Australia, New Zealand, Czechia, and the UK, per the filing.In Australia, the company expects a market reset after the regulatory review is complete, and is working to establish its products in new clinic chains.Elsewhere, Rua plans to bring several products to the New Zealand market in the coming months, and is also working on product launches in Czechia scheduled for May. Additionally, the company is looking to expand in the UK with plans to incorporate its genetics through new channels and clinic chains.In Germany, the company believes there is strong demand for consistent and reliable suppliers as significant regulatory changes seem unlikely following a review during which distributors reduced stock and scaled back imports. The German market remains competitive and continues to show strong signs of growth, Rua said.
$NZE:RUA
Treasury
Market Chatter: Nvidia-Linked Data Center Raises $4.6 Billion From Junk Bond Sale
A Nevada data center project tied to Nvidia (NVDA) has raised $4.59 billion through a junk-bond sale, underscoring a rise in deals for AI infrastructure funding, Bloomberg reported on Tuesday, citing a person familiar with the matter.The deal, backed by Tract Capital Management and Fleet Data Centers, priced five-year notes at a 6.74% yield, the report said.The project, a 200-megawatt facility in Nevada, is expected to be leased to Nvidia.The deal was priced during broader volatility in data center-linked stocks and bonds, as concerns grow over whether the rapid expansion in AI-related spending will deliver expected returns, Bloomberg said.Nvidia did not immediately respond to' request for comment.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)
$NVDA